BioCryst: Board of Directors

George B. Abercrombie
Stanley C. Erck
John L. Higgins
Zola P. Horovitz, Ph.D.
Nancy Hutson, Ph.D.
Peder K. Jensen, M.D.
Kenneth B. Lee, Jr.
Charles A. Sanders, M.D.
Jon P. Stonehouse

George B. Abercrombie

Mr. Abercrombie was appointed to the Board in October 2011. He has over 30 years of experience as a business leader in the pharmaceutical industry, and most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. He began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Currently, Mr. Abercrombie serves as a member of the Board of Directors of Tranzyme Pharma and as Chairman of the Board of Brickell Biotech. Additionally, he is a member of the Board of Directors of Project HOPE and a Senior Scholar at Duke University’s Fuqua School of Business.

Stanley C. Erck

Stanley C. Erck was elected a Director in December 2008. From 2000-2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidates. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of Novavax, MaxCyte, and the MdBio Foundation, a private charitable organization. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.

John L. Higgins

John L. Higgins was elected a Director in May 2004. Mr. Higgins is President and Chief Executive Officer of Ligand Pharmaceuticals Inc., a publicly traded biotech company, since January 2007 and has served as a director since February 2007. Additionally, Mr. Higgins serves on the Board of Techne Corporation, a manufacturer of biotechnology products, and is Chairman of Comentis, a private biotech company. Mr. Higgins was Chief Financial Officer at the biotech company Connetics, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development since January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Prior to joining Connetics, he was a member of the executive management team at BioCryst and prior to joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. He received his A.B. from Colgate University.

Zola P. Horovitz, Ph.D.

Zola P. Horovitz, Ph.D. was elected a director in August 1994. Dr. Horovitz was Vice President of Business Development and Planning at Bristol-Myers Squibb from 1991 until his retirement in April 1994 and previously was Vice President of Licensing at the same company from 1990 to 1991. Prior to that, he spent over 30 years with The Squibb Institute for Medical Research, most recently as Vice President Research, Planning, & Scientific Liaison. He has been an independent consultant in pharmaceutical sciences and business development since his retirement from Bristol-Myers Squibb in April 1994. He is presently Chairman of the Board for BioCryst and also serves as a non-executive on the Board of Directors for Avigen, Inc and GenVec, Inc. Additionally, he serves on the Board of Palatin Technologies, Inc. and DOV Pharmaceuticals.

Nancy Hutson, Ph.D.

Dr. Hutson was appointed to the Board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc. in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as Director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Currently, Dr. Hutson currently serves on the board of directors for Cubist Pharmaceuticals, Inc. and Endo Pharmaceuticals Holdings, Inc., and is an active member on the board of directors for Planned Parenthood of Connecticut. She is also involved in several professional societies, including but not limited to, the American Association for the Advancement of Science and the American Physiological Society. Dr. Hutson received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University.

Peder K. Jensen, M.D.

Peder K. Jensen was appointed to the Board in May 2011. Dr. Jensen has over 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for more than forty new drug approvals in the U.S., Europe and Japan during his career. He most recently served as Corporate Senior Vice President and General Manager, R&D for Japan and Asia/Pacific at Schering-Plough Corporation, and earlier he held a number of global senior R&D positions at Schering-Plough, including Senior Vice President of Clinical Research. Dr. Jensen previously held senior R&D positions at Chiron and Ciba-Geigy, and a number of academic posts. Dr Jensen is also a member of the Board of Acorda Therapeutics, Inc. Dr. Jensen received his M.D. from the University of Copenhagen, where he also completed his post graduate medical training in neurology and internal medicine.

Kenneth B. Lee, Jr.

Kenneth B. Lee, Jr. was appointed to the Board in June 2011. Mr. Lee has over 35 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is currently a general partner for Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young, where he was most recently Managing Director of the firm's health sciences corporate finance group. Mr. Lee was also Chairman of the Ernst & Young Life Sciences Practice and Co-Chairman of Ernst & Young’s International Life Science Parctice. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently an active member on the board of directors of biotech companies Maxygen and Pozen, Inc., as well as the NC Biosciences Organization (NCBIO). Previously, Mr. Lee served on the boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, OSI Pharmaceuticals and A.M. Pappas & Associates.

Charles A. Sanders, M.D.

Charles A. Sanders was appointed to the Board in December 2009. He brings to BioCryst extensive experience as a corporate executive and director, physician and professor of medicine. Dr. Sanders is retired from Glaxo, Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Prior to joining Glaxo, Inc., Dr. Sanders spent eight years with Squibb Corporation, where he held a number of positions, including Vice Chairman. Previously, Dr. Sanders was General Director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Sanders is currently a member of the Institute of Medicine of the National Academy of Sciences and Chairman of Project HOPE and the Foundation for the National Institutes of Health. He is also past Chairman of the UNC Health Care System. Additionally, he serves on the boards of several publicly traded companies, including Cephalon Corporation and Vertex Pharmaceuticals. Dr. Sanders previously served as Lead Director of Genentech until it was acquired in March 2009. He earned his M.D. from the University of Texas Southwestern Medical School.

Jon P. Stonehouse

Jon P. Stonehouse was elected BioCryst Pharmaceuticals, Inc.’s President and Chief Executive Officer in January 2007. Having been a pharmaceutical executive for more than 20 years, Mr. Stonehouse has strong commercialization, financial transaction, business development, and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.